Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

SURFACE ONCOLOGY, INC.

(SURF)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Surface Oncology to Participate in the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit

09/16/2020 | 05:05pm EDT

CAMBRIDGE, Mass., Sept. 16, 2020 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced that Jeff Goater, its chief executive officer, and Robert Ross, M.D., its chief medical officer, will participate in the upcoming Oppenheimer Fall Healthcare Life Sciences & MedTech Summit on September 21, where they will discuss Surface Oncology's lead programs, SRF617 (targeting CD39) and SRF388 (targeting IL-27), as well as Surface’s emerging preclinical pipeline, highlighted by SRF813 (targeting CD112R, also known as PVRIG).

About Surface Oncology:

Surface Oncology is an immuno-oncology company developing next-generation antibody therapies focused on the tumor microenvironment. Its pipeline includes two wholly-owned lead programs targeting CD39 (SRF617) and IL-27 (SRF388), a clinical-stage collaboration with Novartis targeting CD73 (NZV930), and two preclinical programs, each focused primarily on activating natural killer cells (via targeting CD112R, also known as PVRIG (SRF813)) or depleting regulatory T cells (via targeting CCR8 (SRF114)). Surface’s novel cancer immunotherapies are designed to achieve a clinically meaningful and sustained anti-tumor response and may be used alone or in combination with other therapies. For more information, please visit www.surfaceoncology.com.

Contacts:
Investors
Matt Lane
matt@gilmartinir.com
617-901-7698

Media
Tom Donovan
tom@tenbridgecommunications.com
857-559-3397

Primary Logo


© GlobeNewswire 2020
All news about SURFACE ONCOLOGY, INC.
06/10SURFACE ONCOLOGY, INC.  : Submission of Matters to a Vote of Security Holders (f..
AQ
06/04SECTOR UPDATE : Health Care Stocks Trade Higher Pre-Bell Friday
MT
06/04Surface Oncology in Clinical Trial Collaboration With Roche
DJ
06/04SURFACE ONCOLOGY  : to Collaborate With Roche for Testing Liver Cancer Combinati..
MT
06/04SURFACE ONCOLOGY  : SRF388, a First-in-Class IL-27 Antibody, Demonstrates Monoth..
PU
06/04SURFACE ONCOLOGY, INC.  : Other Events, Financial Statements and Exhibits (form ..
AQ
06/04SRF388, a First-in-Class IL-27 Antibody, Demonstrates Monotherapy Activity in..
GL
06/04SURFACE ONCOLOGY  : to Collaborate with Roche on Immuno-Oncology Study Evaluatin..
AQ
06/04Surface Oncology to Collaborate with Roche on Immuno-Oncology Study Evaluatin..
GL
05/18SURFACE ONCOLOGY  : BTIG Initiates Surface Oncology at Buy Rating With $17 Price..
MT
More news
Financials (USD)
Sales 2021 29,8 M - -
Net income 2021 -49,6 M - -
Net Debt 2021 - - -
P/E ratio 2021 -6,34x
Yield 2021 -
Capitalization 318 M 318 M -
Capi. / Sales 2021 10,7x
Capi. / Sales 2022 28,9x
Nbr of Employees 51
Free-Float 90,2%
Chart SURFACE ONCOLOGY, INC.
Duration : Period :
Surface Oncology, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends SURFACE ONCOLOGY, INC.
Short TermMid-TermLong Term
TrendsBearishBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 5
Average target price 16,00 $
Last Close Price 7,32 $
Spread / Highest target 146%
Spread / Average Target 119%
Spread / Lowest Target 91,3%
EPS Revisions
Managers and Directors
NameTitle
Robert W. Ross President, Chief Executive Officer & Director
Jessica Fees Chief Financial Officer
J. Jeffrey Goater Chairman
Vito J. Palombella Chief Scientific Officer
Alison M. O'Neill Chief Medical Officer
Sector and Competitors
1st jan.Capitalization (M$)
SURFACE ONCOLOGY, INC.-20.78%318
GILEAD SCIENCES, INC.14.33%83 541
WUXI APPTEC CO., LTD.24.70%63 775
REGENERON PHARMACEUTICALS11.35%55 705
BIONTECH SE160.57%51 304
VERTEX PHARMACEUTICALS-20.52%48 628